Kornimate/medical-research-clean huggingface dataset:
treatment protocol for hemiplegic shoulder pain

Conditions: Stroke; Hemiplegia; Shoulder Pain

Summary: the purpose of this study is to determine if a specific stretching and strengthening protocol, in addition to current standard treatment, is more effective for treating post-stroke shoulder pain than current standard treatment alone.

current standard treatment of post-stroke shoulder pain includes joint protection (i.e., slings and protective positioning) and stretching/strengthening exercises through a pain-free range. although the added movement of the shoulder blade when moving the post-stroke arm has been recommended in the literature, no studies to date have been found which directly looks at the impact of providing synchronized three-dimensional scapular and humeral movement during therapy. due to the integral relationship between the scapula and the humerus during movement, it is hypothesized that an increase in 3-dimensional shoulder blade mobility in the painful post-stroke shoulder will contribute to increased pain-free 3-dimensional arm movement. this double-blind randomized-controlled study aims to investigate the effectiveness of this 3-d approach at addressing post-stroke shoulder pain.

Eligibility criteria:
inclusion criteria: * diagnosis of shoulder pain secondary to altered alignment and/or neuro-muscular movement patterns post-stroke; * medically stable and 2-24 months post onset of stroke; * between stages of 2-5 of the chedoke-mcmaster stages of upper extremity motor recovery; * not currently receiving any other active neuro-rehabilitation intervention to promote stroke recovery; * cognitively able to provide informed consent, follow specific testing commands, and communicate their level of pain during assessment and treatment. exclusion criteria: * a history of shoulder pain prior to the onset of the stroke; * shoulder pain which is secondary to any history of trauma, fractures, arthritis or joint instability of the neck, spine, ribs, or shoulder girdle before or after the stroke; possible rotator cuff tears; * shoulder-hand syndrome; thalamic or central pain; spinal cord pathology; osteoporosis; * any medical condition which may affect the ability to participate in an active rehabilitation exercise program (i.e., uncontrolled hypertension or angina).

Keywords: cerebral vascular accident stroke hemiplegic shoulder pain range of motion scapula mobilization
a trial to evaluate the safety and preliminary efficacy of ink in the treatment of subjects with solid tumor

Conditions: Solid Tumor

Summary: this trial is to investigate the safety, efficacy of ink in subjects with solid tumor. it is a dose escalation and extension trial.

solid tumor is a disease with high mortality rates. the aim of this trial is to investigate the safety, efficacy of ink in subjects with solid tumor. it is a dose escalation and extension trial.

Eligibility criteria:
inclusion criteria: 1. ≥18 years old. 2. subjects with recurrent or metastatic solid tumors that cannot accept radical locoregional therapy; 3. systemic standard treatment failed or cannot tolerate serious toxicity or lack of standard treatment. 4. have 1 or more focus can be accessed according to recist 1.1 5. eastern cooperative oncology group(ecog):0-1 6. expected survival period over 3 months 7. have acceptable organ function and the results of laboratory examination meet the request below: hepatic insufficiency (alt) and aspartate aminotransferase（ast）≤3xuln(upper limit of normal);total bilirubin≤3xuln；creatinine≤3xuln；white blood cell count ≥3.0x10\^9/l; absolute neutrophil count≥1.0x10\^9/l 8. agree to contraception 9. subjects who understand and voluntarily sign the informed consent form（icf) exclusion criteria: 1. central nervous system metastasis or meningeal metastasis with clinical symptoms； 2. with active infection during screening 3. have serious or uncontrolled basic diseases; 4. have continuous adverse event caused by previous anti-tumor therapy that might affect the evaluation of drug safety； 5. accept anti-tumor therapy within 28 days before first injection; 6. accept general anesthesia surgery or radiation therapy within 28 days before first injection; 7. accept live vaccine or attenuated live vaccine within 28 days before first injection; 8. allergy to known drug components; 9. serous cavity effusion requiring clinical intervention； 10. pregnancy or prepare to pregnant during the treatment; 11. other situations that not suitable to participate into this trial.

Keywords: ink
measuring gait and self-reported pain in patients with osteoarthritis of the knee using placebo/oxycodone/celecoxib.

Conditions: Osteoarthritis

Summary: the purpose of this trial is to evaluate the use of a cross-over trial design in an osteoarthritis population. we will determine the inter- and intra-subject variability in osteoarthritis (oa) endpoints and evaluate if efficacy can be detected by measuring oa endpoints following treatment with 2 different types of analgesics in a crossover study of this design.

methodology study to evaluate the use of a cross over design and gait analysis. the study was terminated by mutual consent with the study site at a meeting on the 1 april 2009, because of slow recruitment due to a high screen fail rate. the study was not stopped for safety reasons.

Eligibility criteria:
inclusion criteria: * subject has been taking an nsaid at least 15 of the past 30 days for index knee pain * grades 2 or 3 oa as defined by the kellgren and lawrence grading system of the medial tibiofemoral joint (joint space narrowing in the medial compartment \> lateral compartment as assessed by x-ray) using the altman atlas of oa7. this must be documented with a report from an x-ray of the study joint taken either at screening or within 1 year prior to screening * subject meets american college of rheumatology (acr) clinical classification criteria for osteoarthritis of the knee, defined by the following: knee pain and at least 3 of the following: oage \>50 omorning stiffness \<30 minutes ocrepitus on active motion obony tenderness obony enlargement ono palpable warmth of synovium. exclusion criteria: * subject has a documented history of an allergic reaction (hives, rash, etc.) or a clinically significant intolerance to celecoxib, sulfonamides, aspirin, or opioids including oxycodone * significant pain outside the index knee, including significant hip or back pain that can not be distinguished from oa pain or that interferes with ability to walk. (patients with bilateral knee oa will be allowed into the study. the index knee should be defined as the more painful knee * predominantly patellofemoral knee osteoarthritis in the index knee as assessed by clinical examination * subject who are unable to discontinue all formulations of prior analgesics other than acetaminophen during the washout period of the study, or who are anticipated to be unable to discontinue rescue medication for 24 hours prior to the respective visits. (low dose aspirin may be taken for cardiac prophylaxis * excessive signal knee joint laxity indicative of functional ligamentous deficiency
convolutional neural network in ovarian follicle identification

Conditions: Infertility, Female; Ovarian Follicular Cyst

Summary: a prospective cohort trial studying patients with infertility undergoing an ovarian stimulation with exogenous gonadotropins. ovarian monitoring will be performed with a combination of transvaginal ultrasound and 2 dimensional human measurements of the follicle development on the right and left ovaries along with sonoavc. human and sonoavc measurements will then be compared to mask region-based convolutional neural network in follicle identification and measurement during during the ovarian stimulation.

this is a prospective cohort trial in which a total of 80 female subjects with infertility between the ages of 21 and 42 years of age undergoing ovarian stimulation will be recruited. after giving informed written consent the subject to undergo standard ovarian ultrasound monitoring with transvaginal ultrasounds during the ovarian stimulation. monitoring will be performed with two-dimensional measurements of each follicle greater than 10 mm in size by the ultrasonographer. sonoavc will then be applied to both ovaries for automated counting and measurement of the follicles within the ovaries. the patient will then undergo two 6-second ultrasounds of the right and left ovaries which will then be transmitted in a dicom format to mask regional based recurrent neural network which is been trained and validated for follicle detection and quantification using curated transvaginal ultrasound images.

Eligibility criteria:
inclusion criteria: * infertile women ages 21-42 years old undergoing ovarian hyperstimulation as part of the treatment care. women with at least one ovary visible with transvaginal ultrasound. women with at least one follicle 10 mm or greater in average diameter. exclusion criteria: * women less than 21 years of age or greater than 42 years of age. women without a visible ovary by transvaginal ultrasound. women without a follicle at least 10 mm in average diameter

Keywords: infertility ovarian follicle
lateral epicondylitis iontophoresis randomized control trial (lerct)

Conditions: Lateral Epicondylitis

Summary: the intent of this double-blinded study is to investigate the short (2 months) and long-term (over 2 months) therapeutic capabilities of iontophoresis.

the intent of this double-blinded study is to investigate the short (2 months) and long-term (over 2 months) therapeutic capabilities of iontophoresis. we anticipate that patients treated with iontophoresis will have improved scores on the vas and dash assessments, and will recover more quickly than those patients receiving the sham treatment. a sham treatment is a method used in medical trials to help researchers determine the effectiveness of a drug/treatment which in this case will be iontophoretic administration using dexamethasone. placebos are inactive substances (saline) used in this study to compare results with an active substance (dexamethasone). furthermore, it is the hope of this research team that through careful analysis and comparison of these two treatment arms a clear conclusion is met regarding the efficacy of iontophoresis as a powerful treatment paradigm for patients suffering from this disorder.

Eligibility criteria:
inclusion criteria * patients who have clinical evidence of lateral epicondylitis - tests: palpation of lateral epicondylitis, resisted wrist extension, middle finger test, manual muscle test * patients who have symptoms (patient provided or documented information will be used to determine how long they have had symptoms) of lateral epicondylitis for at least a month, but no more than 3 months from most recent episode * x-rays must show no evidence of post-traumatic or degenerative arthritis. all patients who present to voi hand \& upper extremity center complaining of lateral epicondylitis symptoms have radiographs taken. patient selection factors include: 1. ability and willingness to follow instructions 2. patients who are able and willing to return for follow-up evaluations 3. patients of all races and genders 4. patients who are able to follow care instructions exclusion criteria * patients less than 18 years old, or older than 75 years old * patients who to their knowledge our pregnant * patients unwillingly or unable to comply with a rehabilitation program, or who indicate difficulty or inability to return for follow-up visits prescribed by the study protocol * patients who qualify for inclusion in the study, but refuse consent to participate in the study * patients who have had non-steroidal anti-inflammatory drugs or systemic corticosteroids/analgesics within three days prior * patients who have local therapeutic modalities, such as: iontophoresis, ultrasound, or heat within the last month * patients who have had: * injection of steroids within the last year or prior surgery * recurrent injury or previous fracture of affected area * history of rheumatoid or degenerative arthritis, carpal tunnel syndrome, rotator cuff abnormalities, neurologic abnormalities, muscular or shoulder dysfunction, peripheral neuropathy, radial nerve entrapment, fracture or tumor to the upper extremity, neck or thoracic pain, or pacemaker use.
mapping novel disease genes for dilated cardiomyopathy

Conditions: Cardiomyopathy, Congestive; Cardiovascular Diseases; Heart Diseases; Heart Failure, Congestive

Summary: to identify new dilated cardiomyopathy genes by genetic linkage and mutational analyses.

background: dilated cardiomyopathy (dcm) is a heritable, genetically heterogeneous disorder causing congestive heart failure. current medical therapy has minimal impact on prognosis and cardiac transplantation is the only definitive treatment for end-stage disease. the molecular and cellular mechanisms underlying dcm are poorly defined, but the importance of single gene defects in disease pathogenesis is becoming increasingly apparent. design narrative: the genetic epidemiology study will identify novel dilated cardiomyopathy genes using genetic linkage and mutational analyses. the first aim is to determine the chromosomal location of novel familial dilated cardiomyopathy genes. this will be accomplished by genome-wide genotyping and genetic linkage analyses in three large families with autosomal dominant dilated cardiomyopathy. previously identified dilated cardiomyopathy genes have been excluded in these families. the second aim is to identify mutations in novel genes that cause familial dilated cardiomyopathy by linkage and sequence analyses of candidate genes mapping to dilated cardiomyopathy loci. once novel genes for familial dilated cardiomyopathy are identified, the third aim will be to determine the role of these genes in a large cohort of unrelated patients with familial and sporadic dilated cardiomyopathy. high throughput dna sequence analyses will be performed to identify additional inherited and de novo mutations.

Eligibility criteria:
no eligibility criteria
sepsis electronic prompting for timely intervention and care for inpatients

Conditions: Sepsis; Electronic Health Records; Clinical Decision Support Systems

Summary: the goal of this clinical trial is to study systemic inflammatory response syndrome (sirs) electronic health record (ehr) alerts for sepsis in the inpatient setting. the main question it aims to answer is: do nurse alerts, prescribing clinician alerts, or both nurse and prescribing clinician alerts improve time to sepsis treatment for patients in the inpatient setting? nurses and prescribing clinicians will receive sirs alerts based on the group to which the patient is randomly assigned. researchers will compare four groups: no alerts, nurse alerts only, prescribing clinician alerts only, or both nurse and prescribing clinician alerts.

septic is a master protocol for two trials on distinct subpopulations: emergency department (ed) patients and inpatients. this protocol "id: aaau1002 - ip" describes the inpatient subpopulation study while "id: aaau1002 - ed" describes the ed subpopulation study. sepsis is a major cause of death both globally and in the united states. early identification and treatment of sepsis are crucial for improving outcomes. international guidelines recommend hospital sepsis screening programs, which are commonly implemented in the electronic health record (ehr) as an interruptive screening alert based on systemic inflammatory response syndrome (sirs) criteria. despite widespread use, it is unknown whether these sepsis screening and alert tools improve the delivery of high-quality sepsis care. this study tests interruptive (pop-up) ehr alerts. epic systems, the company that produces the ehr, refers to these types of alerts as bestpractice advisories (bpas).

Eligibility criteria:
patient inclusion criteria: * age \> 18 years-old * meets sirs criteria * physically located in an inpatient area of the hospital * not located in a hospital unit that takes care of pregnant and peri-partum patients * not sars-cov-2 pcr positive in past 7 days * does not have an active order for "comfort measures only" patient exclusion criteria: * already having sepsis treatment ordered (if prescribing clinician alert) or collected/completed (if nurse alert) * already enrolled in the septic study (including as an emergency department patient or as an inpatient)

Keywords: sepsis alerts clinical decision support systems informatics health information technology
validity and reliability in measuring the subacromial space by using ultrasound

Conditions: Shoulder Impingement

Summary: to investigate validity and reliability in measuring the subacrominal space by using ultrasound


Eligibility criteria:
inclusion criteria: * healthy subjects age range 19-35 years exclusion criteria: * with any pain in the upper extremities and back

Keywords: subacrominal space
a clinical study to evaluate the safety and efficacy of surgical material for nasal septoplasty

Conditions: Septal Deformity; Nasal Obstruction

Summary: the purpose of this clinical trial is to evaluate safety and efficacy of tnr mesh for patients who need nasal septoplasty for septal deformity with nasal obstruction.

nasal obstruction is a nasal disease commonly seen in the area of otolaryngology, and major symptoms include nasal congestion, rhinitis, and etc. nasal septoplasty is a surgery performed to improve above symptoms of nasal obstruction and so far, many surgical technique have been studied. all surgical techniques aimed to improve breathing through the nasal cavity by supporting the end of nose using surgical materials such as autologous bone or nonabsorbable material. in the case of autologous bone transplantation, safety is ensured, but there is a limitation since it causes deficiency of the donor site, and the nasal septum may be altered by a modification of the implanted tissue. in the case of nonabsorbable materials, there is a high risk of side effects such as hyposmia, septal perforation, and occurrence of boil. tnr mesh, as a surgical material for nasal septoplasty has a sufficient flexural strength to support the nasal septum and to overcome the force of returning to a deviated state prior to surgery. animal tests have shown that tnr mesh well supports the nasal septum after surgery and the surrounding tissue is well fused between the pores without inflammatory responses. based on above results, a clinical trial was planned to evaluate the efficacy and safety of tnr mesh as a material for nasal septoplasty.

Eligibility criteria:
inclusion criteria: 1. patients with nasal septal deformity who require surgical treatment 2. females of childbearing potential must have a negative urine pregnancy test, and must not plan to become pregnant during the course of the study. exclusion criteria: 1. known allergic reaction to medical devices(tnr mesh) of the clinical trial 2. pregnancy or lactation - before screening 3. history of surgery in nasal or paranasal sinuses before screening 4. history of radiation treatment at head and neck 5. history of having participated in other clinical trial of a drug/ a medical device within three months - screening point 6. patients with untreated nasal bone fraction or trauma of nasal 7. patients with surgical site infection caused by nasal bone fraction or trauma 8. patients with untreated a perforation of septum, a sinusitis, a nasal cavity polyposis, a nasal cavity sarcoidosis, nasal valve collapse or wegener's granulomatosis 9. patients with inflammation in a nasal cavity 10. patients with sarcoma or carcinoma in a nasal cavity 11. patients with asthma 12. patients with untreated palate-facial disfigurements or cleft palate 13. patients with systemic inflammatory disease 14. patients with sepsis

Keywords: nasal obstruction septal deformity septoplasty tnr mesh polycaprolactone
the genetic and affective prediction study

Conditions: Mental Disorders

Summary: a major proportion of patients admitted to psychiatric acute and emergency departments have symptoms, behaviors or function influenced by implicit or explicit suicidal intention (tendency towards self-harm, or suicide attempt). there is an increased risk of suicide in the acute phase during in-patient stay and after discharge. at present there is no satisfactory tool to predict post-discharge suicide risk. multidimensional rating is expected to have better predictive properties than one-dimensional rating for suicidal behavior during in -patient stay and two years after discharge. multidimensional rating assesses anxiety, panic, agitation, suicidal thoughts and ideations, as well as therapist's reactions during interviews. in the present study the predictive properties of two rating scales for suicidal behavior during in-patient stay and two years after will be compared. one of these is a multidimensional scale: "multidimensional assessment of suicide risk" (maris).


Eligibility criteria:
inclusion criteria: * acute agitated condition * informed consent exclusion criteria: * drug abuse * in-patient stay for a fixed time at regular intervals

Keywords: emergency services, psychiatric prognosis biological markers anxiety panic psychomotor agitation self-injurious behavior
expert, exposure registry riociguat in patients with pulmonary hypertension

Conditions: Hypertension, Pulmonary

Summary: in accordance with the regulatory guidance this registry has been designed to collect information about the long-term safety of adempas in real clinical practice outside the regulated environment of a controlled clinical study.


Eligibility criteria:
inclusion criteria: * female and male patients who start or are on treatment with adempas * written informed consent exclusion criteria: * patients currently participating in an interventional clinical trial